Rhythm Pharmaceuticals, Inc. (RYTM) News

Rhythm Pharmaceuticals, Inc. (RYTM): $20.02

0.63 (+3.25%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter RYTM News Items

RYTM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest RYTM News From Around the Web

Below are the latest news stories about Rhythm Pharmaceuticals Inc that investors may wish to consider to help them evaluate RYTM as an investment opportunity.

Rhythm Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

BOSTON, May 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 12 noon ET.

GlobeNewswire | May 27, 2021

Rhythm Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference - May 27, 2021

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 12 noon ET.

BioSpace | May 26, 2021

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

European Commission decision anticipated in July European Commission decision anticipated in July

GlobeNewswire | May 21, 2021

Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

European Commission decision anticipated in JulyBOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to trans

FinanzNachrichten | May 21, 2021

Rhythm Pharma Receives Positive CHMP Opinion For Setmelanotide - Quick Facts

(RTTNews) - Biopharmaceutical company Rhythm Pharmaceuticals, Inc. (RYTM) announced Friday that the European Medicines Agency''s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for setmelanotide for the treatment of obesity and the control of hunger associated with

Business Insider Markets | May 21, 2021

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR DeficiencyEuropean Commission decision anticipated in July

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for setmelanotide for the treatment of obesity and the control of hunger

BioSpace | May 20, 2021

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 4600.00% and -99.97%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 3, 2021

Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results

-- First U.S. commercial sales of IMCIVREE™ (setmelanotide) completed late in first quarter – -- Late-breaking data presentations at ENDO 2021 demonstrated continued weight loss with setmelanotide at up to nine months in HET obesity, as well as weight loss data in adults and BMI-Z reductions in adolescents with Bardet-Biedl syndrome -- -- Delivered proof-of-concept data from Phase 2 Basket Study in HET POMC, PCSK1 or LEPR deficiencies, and obesity due to SRC1 and SH2B1 deficiencies -- -- Closed $172.5 million public offering and sold Priority Review Voucher for $100 million, providing additional funding to advance continued development of setmelanotide -- BOSTON, May 03, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company co...

Yahoo | May 3, 2021

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | April 13, 2021

7 Beaten Down Stocks with Significant Insider Buying

Insider buying could be a bullish sign for a stock.

Mark Putrino on InvestorPlace | April 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5544 seconds.